CN105050604B - 奥卡西平的快速分散剂型 - Google Patents

奥卡西平的快速分散剂型 Download PDF

Info

Publication number
CN105050604B
CN105050604B CN201480014727.3A CN201480014727A CN105050604B CN 105050604 B CN105050604 B CN 105050604B CN 201480014727 A CN201480014727 A CN 201480014727A CN 105050604 B CN105050604 B CN 105050604B
Authority
CN
China
Prior art keywords
weight
drug
fast
dosage form
dispersing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480014727.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105050604A (zh
Inventor
J·雅各布斯
K·卡普托
M·吉略特
K·J·苏尔茨鲍
T·G·韦斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceuticals Pharmaceutical Co Ltd
Original Assignee
Aprecia Pharmaceuticals Co
Aprecia Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprecia Pharmaceuticals Co, Aprecia Pharmaceuticals LLC filed Critical Aprecia Pharmaceuticals Co
Publication of CN105050604A publication Critical patent/CN105050604A/zh
Application granted granted Critical
Publication of CN105050604B publication Critical patent/CN105050604B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • B29C64/165—Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0058—Liquid or visquous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480014727.3A 2013-03-15 2014-03-14 奥卡西平的快速分散剂型 Active CN105050604B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791726P 2013-03-15 2013-03-15
US61/791,726 2013-03-15
PCT/US2014/028125 WO2014143935A1 (en) 2013-03-15 2014-03-14 Rapidly dispersible dosage form of oxcarbazepine

Publications (2)

Publication Number Publication Date
CN105050604A CN105050604A (zh) 2015-11-11
CN105050604B true CN105050604B (zh) 2021-10-26

Family

ID=51537567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480014727.3A Active CN105050604B (zh) 2013-03-15 2014-03-14 奥卡西平的快速分散剂型

Country Status (10)

Country Link
US (4) US9314429B2 (enExample)
EP (1) EP2968354B1 (enExample)
JP (2) JP6463333B2 (enExample)
CN (1) CN105050604B (enExample)
AU (2) AU2014228063B2 (enExample)
CA (1) CA2906107C (enExample)
ES (1) ES2761265T3 (enExample)
HK (1) HK1213472A1 (enExample)
MX (1) MX364381B (enExample)
WO (1) WO2014143935A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US10716648B2 (en) * 2014-05-02 2020-07-21 University Of Louisville Research Foundation, Inc. Methods for fabricating dental restorations
EP4512394A3 (en) 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
CN105770899A (zh) * 2016-03-07 2016-07-20 北京诺康达医药科技有限公司 一种大剂量药物的速释制剂及其制备方法
AU2017235598A1 (en) * 2016-03-18 2018-08-09 Grünenthal GmbH Floating pharmaceutical dosage form
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) 2016-07-25 2016-09-07 Univ Central Lancashire Solid dosage form production
CA3051614A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US10703549B2 (en) * 2017-06-30 2020-07-07 The Procter And Gamble Company Water soluble containers and methods of making them
WO2019081540A1 (en) * 2017-10-26 2019-05-02 Merck Patent Gmbh METHODS FOR ACHIEVING CELL CULTURE
US11571391B2 (en) 2018-01-09 2023-02-07 Triastek, Inc. Oral drug dosage forms compromising a fixed-dose of an ADHD non-stimulant and an ADHD stimulant
US12544446B2 (en) 2018-03-02 2026-02-10 Vitiprints, LLC Printed delivery device having supplements
EP3866757B1 (en) 2018-10-15 2022-08-10 Aprecia Pharmaceuticals LLC Method and system for forming a dosage form within a packaging
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
CA3126903A1 (en) 2019-01-18 2020-07-23 Ihi Corporation Thrust foil bearing
EP3789015A1 (en) * 2019-09-05 2021-03-10 Universität Innsbruck Fast consolidating compounds
ES2828509B2 (es) 2019-11-26 2022-03-09 Fund Idonial Composicion para la impresion 3d de farmacos semisolidos
WO2021211898A2 (en) * 2020-04-15 2021-10-21 Aprecia Pharmaceuticals LLC Multi-component packaged dosage form and method
AU2021296908A1 (en) 2020-06-26 2023-02-16 Aprecia Pharmaceuticals LLC Rapidly-orodispersible tablets having an interior cavity
KR20250008880A (ko) 2022-04-13 2025-01-16 아프레시아 파마슈티칼즈 엘엘씨 전방향 자기 운동 장치를 이용한 적층 제조를 위한 시스템 및 방법
JP2025526158A (ja) * 2022-08-18 2025-08-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固体薬剤投与形態の製造のためのプロセス
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa
FR3162625A1 (fr) * 2024-05-30 2025-12-05 Mb Therapeutics Formulation pharmaceutique imprimable par extrusion, cartouche d’impression renfermant une telle formulation et procédé de préparation d’un médicament la mettant en œuvre

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036738A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
CN101336105A (zh) * 2006-01-31 2008-12-31 特瓦制药工业有限公司 奥卡西平药物制剂及其制备方法，其中奥卡西平具有宽且多峰的粒度分布

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
EP1194153B1 (en) 1999-07-09 2004-05-06 Ortho-McNeil Pharmaceutical, Inc. Taste masked pharmaceutical liquid formulations
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
AU2001263506A1 (en) * 2000-05-18 2001-11-26 Massachusetts Institute Of Technology Encapsulating a toxic core within a non-toxic region in an oral dosage form
CA2440069A1 (en) 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
KR20040002976A (ko) * 2001-05-18 2004-01-07 랜박시 래보러터리스 리미티드 옥스카르바제핀 제형
US20030099708A1 (en) * 2001-10-29 2003-05-29 Therics, Inc Printing or dispensing a suspension such as three-dimensional printing of dosage forms
CN1688292A (zh) 2002-09-04 2005-10-26 兰贝克赛实验室有限公司 掩味剂型及其制造方法
AU2003302881A1 (en) 2002-12-11 2004-06-30 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
CN1819819B (zh) 2003-05-07 2011-03-09 株式会社三养社 用于制备速熔片的高度可塑性颗粒
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US20070154550A1 (en) 2003-08-28 2007-07-05 Potdar Arti Pharmaceutical composition comprising anticonvulsant with taste mask coating
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US20060182796A1 (en) 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
EP2029118A2 (en) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
WO2007121523A1 (en) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
WO2008141751A2 (en) * 2007-05-23 2008-11-27 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
ES2758624T3 (es) 2009-02-12 2020-05-06 Fuji Chem Ind Co Ltd Composición de partículas desintegrantes y material de desintegración rápida moldeado por compresión que comprende la misma
US20100285130A1 (en) 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
CN102802614A (zh) 2009-06-04 2012-11-28 巴斯夫欧洲公司 含有被遮味活性成分的口腔崩解剂型
CA2771358A1 (en) 2009-08-19 2011-02-24 Sascha General Drug delivery systems (wafer) for pediatric use
AR079862A1 (es) 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036738A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
CN101336105A (zh) * 2006-01-31 2008-12-31 特瓦制药工业有限公司 奥卡西平药物制剂及其制备方法，其中奥卡西平具有宽且多峰的粒度分布

Also Published As

Publication number Publication date
EP2968354A4 (en) 2016-01-20
CN105050604A (zh) 2015-11-11
US20170172919A1 (en) 2017-06-22
US20160250145A1 (en) 2016-09-01
EP2968354A1 (en) 2016-01-20
WO2014143935A1 (en) 2014-09-18
HK1214173A1 (en) 2016-07-22
AU2014228063B2 (en) 2017-04-20
US9314429B2 (en) 2016-04-19
JP6463333B2 (ja) 2019-01-30
ES2761265T3 (es) 2020-05-19
MX2015012136A (es) 2015-11-25
AU2017203365A1 (en) 2017-06-08
AU2014228063A1 (en) 2015-10-08
US9616018B2 (en) 2017-04-11
EP2968354B1 (en) 2019-11-13
US20150366802A1 (en) 2015-12-24
MX364381B (es) 2019-04-25
WO2014143935A4 (en) 2014-11-20
AU2017203365B2 (en) 2019-07-25
JP2016513724A (ja) 2016-05-16
CA2906107C (en) 2021-08-24
US20180296479A1 (en) 2018-10-18
US10028909B2 (en) 2018-07-24
CA2906107A1 (en) 2014-09-18
JP2019006812A (ja) 2019-01-17
HK1213472A1 (zh) 2016-07-08

Similar Documents

Publication Publication Date Title
JP6463333B2 (ja) オキシカルバゼピンの急速分散性の剤形
CN105188849B (zh) 包含左乙拉西坦的快速分散剂型
JP6466399B2 (ja) トピラマートの急速分散性の剤形
US11065207B2 (en) Oral dosage form
HK1214173B (en) Rapidly dispersible dosage form of oxcarbazepine
HK40009940A (en) Rapid disperse dosage form containing levetiracetam
HK40009940B (en) Rapid disperse dosage form containing levetiracetam
HK1214768B (en) Rapidly dispersible dosage form of topiramate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213472

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180626

Address after: ohio

Applicant after: Pharmaceuticals Pharmaceutical Co., Ltd.

Address before: American Pennsylvania

Applicant before: APRECIA PHARMACEUTICALS COMPANY

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1213472

Country of ref document: HK